Abstract: The present invention relates to a peptide SSTP1 that modulates IL6 pathway to induce apoptosis in cells where there is overexpression of IL6R? (Interleukin 6 Receptor). This is achieved by inhibiting IL6/JAK/STAT pathway and/or by activating JNK/AP1 signal transduction pathway. The sensitivity of the cancer cells to SSTP1 was proportional to IL6R? levels. Further, SSTP1 kills triple negative breast cancer cells, MDA-MB-231, at a concentration that cause neither hemolysis nor cell death to blood cells. The peptide of the present invention utilizes the elements of IL6 pathway and induces apoptosis in cancer cells. SSTP1 functions by activation of JNK/AP1 pathway with concomitant inhibition of STATs, offering a new therapeutic strategy to treat cancer cells that overexpress IL6R?.
Abstract: Antiviral polypeptides and methods of use are provided herein. In particular, these polypeptides can comprise the Yodha amino acid sequence, variants, derivatives, or truncated versions thereof. In certain embodiments, this disclosure relates to uses of the peptides, nucleic acid molecules, and compositions disclosed herein to treat or prevent a viral infection.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
June 6, 2023
Assignees:
Emory University, Rajiv Gandhi Centre for Biotechnology
Inventors:
Sanil George, Joshy Jacob, David Holthausen, Song Hee Lee, Jessica Shartouny
Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.
Type:
Grant
Filed:
October 26, 2012
Date of Patent:
May 1, 2018
Assignees:
Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology
Abstract: This invention relates to a simple end point assay for detection of transient intracellular Ca2+ with broad applicability to many Ca2+ channel proteins comprising, Generation of expression constructs for the fusion proteins having the Ca2+/calmodulin dependent protein kinase II (CaMKII) phosphorylation sites of NR2A or NR2B subunits of N-methyl-D-aspartate receptor (NMDAR) or the voltage gated potassium channel of Drosophila (Eag) or any protein sequence which binds to the T-site of CaMKII similar to NR2B, conjugated to mitochondrial localizing signal sequence, or mutants of these sequences as described herein. Generation of mammalian expression constructs of ?-CaMKll as a chimera with green fluorescent protein (GFP-?-CaMKII) or its mutants as described herein.
Type:
Grant
Filed:
June 12, 2008
Date of Patent:
November 6, 2012
Assignees:
Rajiv Gandhi Centre for Biotechnology, Department of Biotechnology
Abstract: A novel polymer support for solid phase peptide synthesis comprising polystyrene backbone and propoxylate function of hexanedioldiacrylate crosslinks having optimum hydrophilic/hydrophobic balance and a process of preparation thereof.
Type:
Grant
Filed:
July 24, 2003
Date of Patent:
November 14, 2006
Assignees:
Rajiv Gandhi Centre for Biotechnology, The Secretary, Department of Biotechnology
Abstract: A novel polymer support for solid phase peptide synthesis comprising polystyrene backbone and propoxylate function of hexanedioldiacrylate crosslinks having optimum hydrophilic/hydrophobic balance and a process of preparation thereof.
Type:
Application
Filed:
July 24, 2003
Publication date:
January 27, 2005
Applicant:
Rajiv Gandhi Centre for Biotechnology, Peptide Laboratory